Company Vaccinex, Inc.

Equities

VCNX

US9186403013

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-05 pm EDT			5-day change	1st Jan Change
6.41 ^USD	-10.63%		+28.20%	-31.13%

May. 16	Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	MT
Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Number of employees: 39

USD in Million	2022	Weight	2023	Weight	Delta
Biotherapeutics 100.0 %	0	100.0 %	1	100.0 %	+107.27%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	1	100.0 %	+107.27%

Managers	Title	Age	Since
Maurice Zauderer FOU	Founder	78	96-12-31
Elizabeth Evans COO	Chief Operating Officer	52	01-04-30
Ernie Smith CTO	Chief Tech/Sci/R&D Officer	52	01-05-31
John Leonard PRN	Corporate Officer/Principal	77	-

Members of the board	Title	Age	Since
Bala S. Manian BRD	Director/Board Member	77	04-11-30
Albert Friedberg CHM	Chairman	77	96-12-31
Chrystyna Stecyk BRD	Director/Board Member	61	20-05-13
Gerald van Strydonck BRD	Director/Board Member	79	03-02-28
Maurice Zauderer FOU	Founder	78	96-12-31
Barbara Yanni BRD	Director/Board Member	69	15-01-31
Jacob Frieberg BRD	Director/Board Member	67	15-01-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,584,305	1,464,803 ( 92.46 %)	5 ( 0.000316 %)	92.46 %

Name	Equities	%	Valuation
Friedberg Mercantile Group Ltd. /Friedberg Family/ 40.67 %	579,319	40.67 %	3 M $
Armistice Capital LLC 10.18 %	145,000	10.18 %	859 995 $
Maurice Zauderer 9.950 %	141,745	9.950 %	840 690 $
Point72 Asset Management LP 8.181 %	116,546	8.181 %	691 234 $
AIGH Capital Management LLC 4.097 %	58,365	4.097 %	346 163 $
Albert Friedberg 0.1470 %	2,094	0.1470 %	12 420 $
Telemetry Investments LLC 0.1391 %	1,981	0.1391 %	11 749 $
Jacob Frieberg 0.1175 %	1,674	0.1175 %	9 928 $
Morgan Stanley & Co. LLC 0.0781 %	1,113	0.0781 %	6 601 $
Tower Research Capital LLC 0.0734 %	1,045	0.0734 %	6 198 $

Vaccinex, Inc.

1895 Mount Hope Avenue

14620, Rochester

http://www.vaccinex.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VACCINEX, INC.	-31.13%	11.36M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	123B
REGENERON PHARMACEUTICALS, INC.	+14.53%	107B
BIONTECH SE	-2.88%	24.01B
ARGENX SE	+2.18%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-41.04%	16.84B
BEIGENE, LTD.	-11.83%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.46%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.22%	11.32B

Bio Therapeutic Drugs